Literature DB >> 8787538

DNA filter elution: a window on DNA damage in mammalian cells.

K W Kohn1.   

Abstract

This personal account traces a series of studies that led from DNA physical chemistry to anticancer drug mechanisms. Chemical crosslinking as a basis for anticancer drug actions had been suspected since the time of the first clinical reports of the effectiveness of nitrogen mustard in 1946. After the elucidation of the DNA helix-coil transition, several nearly concurrent findings in the early 1960s established the paradigm of DNA interstrand crosslinking. The DNA filter elution phenomenon was discovered in the early 1970s, and lent itself to the development of practical assays for DNA crosslinks and other DNA lesions in mammalian cells. The assays allowed studies of the effects of DNA damaging agents at pharmacologically or toxicologically relevant doses, and have been widely applied in studies of mutagenic and chemotherapeutic agents. During the period 1979-1986, DNA filter elution studies led to the paradigm of DNA topoisomerases as targets of anticancer drug action, and this has become one of the most active areas of anticancer drug development.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8787538     DOI: 10.1002/bies.950180613

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  9 in total

1.  Fluid mechanics of DNA double-strand filter elution.

Authors:  George Rudinger; Ed Robert Blazek
Journal:  Biophys J       Date:  2002-01       Impact factor: 4.033

2.  Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.

Authors:  Dhriti Sooryakumar; Thomas S Dexheimer; Beverly A Teicher; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2011-06-02       Impact factor: 6.261

3.  Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer.

Authors:  Victoria L Luchenko; Crystal D Salcido; Yongwei Zhang; Keli Agama; Edina Komlodi-Pasztor; Robert F Murphy; Giuseppe Giaccone; Yves Pommier; Susan E Bates; Lyuba Varticovski
Journal:  Cell Cycle       Date:  2011-09-15       Impact factor: 4.534

4.  Selective induction of apoptosis in Hep 3B cells by topoisomerase I inhibitors: evidence for a protease-dependent pathway that does not activate cysteine protease P32.

Authors:  P N Adjei; S H Kaufmann; W Y Leung; F Mao; G J Gores
Journal:  J Clin Invest       Date:  1996-12-01       Impact factor: 14.808

5.  Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.

Authors:  Zhiyong Liao; Robert W Robey; Josée Guirouilh-Barbat; Kenneth K W To; Orsolya Polgar; Susan E Bates; Yves Pommier
Journal:  Mol Pharmacol       Date:  2007-11-05       Impact factor: 4.436

6.  Synthesis of a peptide-universal nucleotide antigen: towards next-generation antibodies to detect topoisomerase I-DNA covalent complexes.

Authors:  Angela L Perkins; Kevin L Peterson; Thomas G Beito; Karen S Flatten; Scott H Kaufmann; Daniel A Harki
Journal:  Org Biomol Chem       Date:  2016-04-26       Impact factor: 3.876

7.  Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2.

Authors:  Jirouta Kitagaki; Keli K Agama; Yves Pommier; Yili Yang; Allan M Weissman
Journal:  Mol Cancer Ther       Date:  2008-08       Impact factor: 6.261

8.  Aminoflavone induces oxidative DNA damage and reactive oxidative species-mediated apoptosis in breast cancer cells.

Authors:  Lancelot McLean; Ubaldo Soto; Keli Agama; Jawad Francis; Randi Jimenez; Yves Pommier; Lawrence Sowers; Eileen Brantley
Journal:  Int J Cancer       Date:  2008-04-01       Impact factor: 7.396

9.  ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair.

Authors:  Masataka Tsuda; Kosai Cho; Masato Ooka; Naoto Shimizu; Reiko Watanabe; Akira Yasui; Yuka Nakazawa; Tomoo Ogi; Hiroshi Harada; Keli Agama; Jun Nakamura; Ryuta Asada; Haruna Fujiike; Tetsushi Sakuma; Takashi Yamamoto; Junko Murai; Masahiro Hiraoka; Kaoru Koike; Yves Pommier; Shunichi Takeda; Kouji Hirota
Journal:  PLoS One       Date:  2017-11-17       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.